ArticleEpilepsia open2019
Clinical features and treatment outcomes of Juvenile myoclonic epilepsy patients.
Article in Epilepsia open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Brivaracetam monotherapy in juvenile myoclonic epilepsy: a safety and efficacy evaluation.Therapeutic advances in neurological disorders · 2026Article
- A meta-analytic evaluation of the efficacy and safety of levetiracetam for treating myoclonic seizures.Heliyon · 2025Article
- Thalamocortical circuits in generalized epilepsy: Pathophysiologic mechanisms and therapeutic targets.Neurobiology of disease · 2023Review
- Juvenile Myoclonic Epilepsy: Seizure and Social Outcomes in Taiwan.Healthcare (Basel, Switzerland) · 2023Article
- Differences in the distribution of triggers among resting state networks in patients with juvenile myoclonic epilepsy explained by network analysis.Frontiers in neuroscience · 2023Article
- Individualised prediction of drug resistance and seizure recurrence after medication withdrawal in people with juvenile myoclonic epilepsy: A systematic review and individual participant data meta-analysis.EClinicalMedicine · 2022Article
- The association between temperament features and childhood traumas in patients with juvenile myoclonic epilepsyTurkish journal of medical sciences · 2020Article
- Pharmacological Management of the Genetic Generalised Epilepsies in Adolescents and Adults.CNS drugs · 2020Review
- Clinical features and treatment outcomes of Juvenile myoclonic epilepsy patients.Epilepsia open · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to evaluate the clinical features and treatment outcomes of patients with juvenile myoclonic epilepsy (JME) in western China.
methodWe continuously reviewed one hundred and five outpatients with JME who were diagnosed and treated at the Epilepsy Registration Center of West China Hospital between October 2012 and July 2014. Seizure control stratified into different seizure types and by antiepileptic drugs (AEDs) was prospectively evaluated every 3-6 months.
resultsAmong 105 patients with JME, eighty-five patients (81%) received monotherapy including valproate (VPA, 47%) and levetiracetam (LEV, 43%) treatment. The rates of seizure freedom 1, 3, and 5 years after the initiation of AED treatment were 64.8% (68/105), 29.5% (31/105), and 14.6% (12/82) in JME patients, respectively. Patients with myoclonic seizure (MS) and absence seizure (AS) were less frequently seizure-free than those with MS and generalized tonic-clonic seizure (GTCS) ( SIGNIFICANCE: Our data suggest that in JME, seizure control is linked to seizure type, possibly allowing a more individualized approach when counseling JME patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.